Combination of viral promoter sequences to generate highly active promoters for heterologous therapeutic protein over-expression in plants

Rancé, Iann; Norre, Frédéric; Gruber, Véronique; Theisen, Manfred

doi:10.1016/s0168-9452(02)00031-6

Cited by 18 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Xho ‐ and Sac I‐ digested PRS‐pro Der p 1 sequence was cloned into Xho I– Sac I sites of pBSKII (Stratagene, La Jolla, CA, USA), leading to plasmid pMRT1831. The pro Der p 1 wild‐type (pDWT) construct was created by inserting the Hpa I– Sac I coding sequence of pMRT1831 downstream of the constitutive Mpr1163 promoter [27].…”

Section: Methodsmentioning

confidence: 99%

Production of native and modified recombinant Der p 1 molecules in tobacco plants

Burtin¹,

Chabre

Olagnier³

et al. 2009

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Production of native and modified recombinant Der p 1 molecules in tobacco plants

Burtin¹,

Chabre

Olagnier³

et al. 2009

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…In some cases, the aim is simply to increase the activity of an endogenous promoter, which can be achieved in the case of the CaMV 35S promoter by duplicating its enhancer elements, a strategy that also works when these elements are imported into other promoters. Chimeric promoters have also been engineered using sequences from the CoYMV and CsVMV major transcript promoters as activating sequences to augment the CaMV 35S promoter, resulting in higher activity compared to CaMV 35S in stably transformed tobacco plants and higher activity compared to corn c-zein in corn endosperm (Rancé et al 2002). In other cases, it is desirable to constrain promoter activity in some way, which has been achieved with synthetic auxin response elements that make heterologous promoters more auxin-sensitive.…”

Section: Alternative Solutionsmentioning

confidence: 99%

Promoter diversity in multigene transformation

et al. 2010

View full text Add to dashboard Cite

Multigene transformation (MGT) is becoming routine in plant biotechnology as researchers seek to generate more complex and ambitious phenotypes in transgenic plants. Every nuclear transgene requires its own promoter, so when coordinated expression is required, the introduction of multiple genes leads inevitably to two opposing strategies: different promoters may be used for each transgene, or the same promoter may be used over and over again. In the former case, there may be a shortage of different promoters with matching activities, but repetitious promoter use may in some cases have a negative impact on transgene stability and expression. Using illustrative case studies, we discuss promoter deployment strategies in transgenic plants that increase the likelihood of successful and stable multiple transgene expression.

show abstract

“…Promoters are often patchworks of different cis-acting elements with defined functions, and novel chimeric promoters with bespoke activity can be created by combining elements from two or more promoters, e.g. a modified CaMV 35S promoter containing sequences from two other viruses was more active than the native CaMV 35S promoter in tobacco plants and more active than the maize -zein promoter in maize seeds [96]. The functional elements from different promoters can also be resolved to a consensus sequence [97] or embedded in a synthetic background to generate a series of non-homologous promoters with the same activity [98].…”

Section: Avoiding Repetitive Sequencesmentioning

confidence: 99%

Optimizing the Yield of Recombinant Pharmaceutical Proteins in Plants

Twyman¹,

Schillberg²,

Fischer

2013

CPD

View full text Add to dashboard Cite

The production of recombinant pharmaceutical proteins in plants is entering a new phase with the recent approval of recombinant glucocerebrosidase produced in carrot cells and the successful production of clinical-grade proteins in diverse plant-based production platforms. In the long journey from concept to product, the field of molecular farming has faced technical and economic hurdles, many reflecting the initially limited productivity of plants compared to established platforms such as mammalian cells. This challenge has been met by innovative research aiming to increase recombinant protein yields and maximize the economic benefits of plants. Research has focused on increasing the intrinsic yield capability of plants by optimizing expression construct design, and also on novel strategies to avoid epigenetic silencing and environmental effects on protein accumulation. In this article, we discuss the diverse approaches that have been used to increase the productivity of plant-based platforms for the production of recombinant pharmaceutical proteins and consider future opportunities to maximize the potential of plants and increase their competitiveness outside niche markets.

show abstract

Combination of viral promoter sequences to generate highly active promoters for heterologous therapeutic protein over-expression in plants

Cited by 18 publications

References 39 publications

Production of native and modified recombinant Der p 1 molecules in tobacco plants

Production of native and modified recombinant Der p 1 molecules in tobacco plants

Promoter diversity in multigene transformation

Optimizing the Yield of Recombinant Pharmaceutical Proteins in Plants

Contact Info

Product

Resources

About